Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Cambridge Cognition wins £1 million contract as the
cognitive assessment partner for pivotal autoimmune trial
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a contract worth just over £1 million with a top 10 pharmaceutical company to provide digital cognitive assessments for a pivotal phase III autoimmune disease trial. Revenue from the contract is expected over the next three years.
Autoimmune diseases occur when a person's immune system mistakenly attacks healthy cells1 which, for some patients, can result in cognitive impairment. With the prevalence of autoimmune disease on the rise2, there is an urgency to develop better treatments. This need has resulted in a 40% increase in clinical trials for autoimmune conditions in the last decade3. Nevertheless, treatment options for the associated cognitive impairment are limited.
This top 10 pharmaceutical company has selected Cambridge Cognition as the cognitive assessment provider for its pivotal trial as they believe the Company has the technology and infrastructure to deliver rapid, sensitive cognitive assessments at scale. The trial aims to recruit and test hundreds of participants across nearly 40 countries.
Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:
"Phase III clinical trials are the large, final stage in drug development as pharmaceutical companies can use the results to seek regulatory approval. Cambridge Cognition is well positioned to deliver these pivotal, global trials with its gold standard solutions. Strategically, this contract sees the Company operate in a high growth space with a leading pharmaceutical company that is committed to tackling diseases in this therapeutic area."
References
1. https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm
2. Dinse GE, Parks CG, Weinberg CR, Co CA, Wilkerson J, Zeldin DC, Chan EKL, Miller FW. Increasing Prevalence of Antinuclear Antibodies in the United States. Arthritis Rheumatol. 2020 Jun;72(6):1026-1035. doi: 10.1002/art.41214. Epub 2020 Apr 30. PMID: 32266792; PMCID: PMC7255943.
3. Informa Trial Trove Search: Autoimmune Trials Search 2010 - 2020
For further information, contact:
| Cambridge Cognition Holdings Plc Matthew Stork, Chief Executive Officer Sally Jennings, Head of Marketing & Communications | Tel: 012 2381 0700 |
| Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: 020 7886 2968
|
| Dowgate Capital Limited (Joint Broker) David Poutney / James Serjeant | Tel: 020 3903 7715
|
| IFC Advisory Ltd (Financial PR and IR) Tim Metcalfe / Graham Herring / Zach Cohen | Tel: 020 3934 6630
|
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
